Xoma Corp. will license its monoclonal antibody ING-1 andcertain technologies to Sterling Drug Inc., the companyannounced Monday.
Sterling will hold an exclusive, worldwide license to ING-1,currently in preclinical testing as a diagnostic and therapeuticfor several cancers. Sterling will carry out all furtherdevelopment of the antibody. Xoma will also give Sterling anon-exclusive license to certain genetic engineeringtechnologies for cancer applications, according to theagreement.
Xoma will receive a technology access fee and royalties fromsales of the resulting products. The Berkeley, Calif., companyis not disclosing the dollar amounts, said spokeswoman CarolDeGuzman.
Xoma said it is seeking to license certain of its cancer-relatedprograms so it can focus on products for infectious diseasesand immune system disorders. -- RF
(c) 1997 American Health Consultants. All rights reserved.